Design Therapeutics (DSGN) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 63.6% versus a loss of 1.5%. Over five years, DSGN leads with a -18.2% price change compared with -88.3% for GYRE. Gyre Therapeutics is the larger company by market cap ($746.5 million vs $729.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | GYRE |
|---|---|---|
| Share price | $11.65 | $7.04 |
| Market cap | $729.08M | $746.48M |
| 1-day change | +1.39% | +4.14% |
| YTD return | +24.20% | -0.28% |
| 1-year return | +63.62% | -1.54% |
| 5-year return | -18.25% | -88.27% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-1.20 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $9.42 |
| 52-week low | $5.28 | $5.44 |
| Distance from 52-week high | -32.46% | -25.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +86.35% | +165.20% |
| Average volume | 604.06K | 105.93K |
| Shares outstanding | 62.58M | 106.03M |
| Employees | 55 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed GYRE by 65.2 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
DSGN vs GYRE FAQ
Which is bigger, Design Therapeutics or Gyre Therapeutics?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $746.48M compared with $729.08M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or GYRE?
DSGN returned +63.62% over the past 12 months, compared with -1.54% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.